WALTHAM, Mass.– BostonGene, a leading provider of artificial intelligence (AI)-driven molecular and immune profiling solutions, today announces it was named a Fierce Life Sciences Innovation Awards winner by Fierce Biotech and Fierce Pharma in the AI innovation category. The program showcases outstanding solutions that are driving improvements and transforming the industry.
BostonGene’s award-winning innovation addresses critical challenges in pathology. Traditional pathology relies heavily on manual slide analysis, which is time-consuming and prone to variability and human error. BostonGene’s advanced AI-based digital pathology platform automates tissue analysis, delivering fast, accurate and reproducible insights across several methodologies, including hematoxylin and eosin (H&E) slides, immunohistochemistry (IHC) and multiplex immunofluorescence (MxIF).
BostonGene’s digital pathology platform incorporates several key innovations:
- Enhanced H&E Analysis: The platform’s AI models analyze whole slide images pixel-by-pixel, accurately identifying complex features such as tertiary lymphoid structures and stromal tumor-infiltrating lymphocytes (sTILs) that can predict response to immunotherapy and patient prognosis. BostonGene’s AI-based pathology reduced the time required to analyze 100 slides from 17 hours of manual analysis to 20 minutes.
- Precision IHC Biomarker Assessment: The platform achieves over 90% accuracy in assessing key biomarkers like PD-L1, which is critical for immunotherapy decisions, and Ki-67, which predicts tumor growth. Its advanced capabilities include analyzing novel drug targets and distinguishing complex staining patterns, such as HER2 expression levels.
- Comprehensive MxIF Analysis: The platform identifies up to 60 markers on a single slide, offering unparalleled insights into tumor microenvironments, including cell-cell interactions, spatial relationships, and cellular communities.
“Our AI-powered solutions ensure precision and reproducibility while providing actionable insights that guide patient care and accelerate drug development,” said Nathan Fowler, MD, Chief Medical Officer at BostonGene. “This award recognizes our relentless commitment to innovation. It underscores the profound impact that digital pathology can have in advancing precision medicine.”
“The Innovation Awards winners showcase the organizations that have demonstrated innovative solutions that have the greatest potential to save money, engage patients or revolutionize the healthcare industry,” says Rebecca Willumson, SVP and Publisher of Fierce Biotech and Fierce Pharma. “We are very pleased to congratulate the winners on their accomplishments.”
An expert panel of judges reviewed the hundreds of awards submissions and determined which companies demonstrated innovative technologies and services that have the potential to make the greatest impact for biotech and pharma companies.
